Unicycive Therapeutics (UNCY) Gains from Investment Securities (2020 - 2026)
Unicycive Therapeutics posted quarterly Gains from Investment Securities of $4.8 million for Q1 2026, up 143.95% year-on-year from $2.0 million in Q1 2025, and up 336.45% on a QoQ basis from -$2.0 million in Q4 2025.
Unicycive Therapeutics (UNCY) has 7 years of Gains from Investment Securities data on file, last reported at $4.8 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 143.95% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 32.46% YoY), and the FY2025 full-year result was $2.0 million, up 48.72% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $4.8 million, up from -$2.0 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $11.8 million in Q1 2024 and bottomed at -$2.0 million in Q4 2025.
- The 5-year median for Gains from Investment Securities is $1.3 million (2022), against an average of $2.4 million.
- The widest annual swing landed in 2024, when Gains from Investment Securities soared 8087.5%; it then sank 135.3% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $1.3 million in 2022, then plunged by 105.36% to -$72000.0 in 2023, then jumped by 8087.5% to $5.8 million in 2024, then tumbled by 135.3% to -$2.0 million in 2025, then surged by 336.45% to $4.8 million in 2026.
- The last three Gains from Investment Securities figures came in at $4.8 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.80 Mn |
| Mar 31, 2026 | 4.80 Mn |
| Dec 31, 2025 | -2.03 Mn |
| Dec 31, 2025 | -2.03 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -374,000.00 |
| Jun 30, 2025 | -374,000.00 |
| Mar 31, 2025 | 1.97 Mn |
| Mar 31, 2025 | 1.97 Mn |
| Dec 31, 2024 | 5.75 Mn |
| Dec 31, 2024 | 5.75 Mn |
| Sep 30, 2024 | -1.75 Mn |
| Sep 30, 2024 | -1.75 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Mar 31, 2024 | 11.81 Mn |
| Mar 31, 2024 | 11.81 Mn |
| Dec 31, 2023 | -72,000.00 |
| Dec 31, 2023 | -72,000.00 |
| Sep 30, 2023 | -1.40 Mn |
| Sep 30, 2023 | -1.40 Mn |
| Jun 30, 2023 | 1.33 Mn |
| Jun 30, 2023 | 1.33 Mn |
| Mar 31, 2023 | 10.38 Mn |
| Mar 31, 2023 | 10.38 Mn |
| Dec 31, 2022 | 1.34 Mn |
| Dec 31, 2022 | 1.34 Mn |
| Jun 30, 2021 | 132,093.00 |
| Jun 30, 2021 | 132,093.00 |
| Dec 31, 2020 | 786,047.00 |
| Dec 31, 2020 | 786,047.00 |